STOCK TITAN

Indivior (INDV) director receives 6,518 RSUs, boosting stake to 27,087 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Stejbach Mark reported acquisition or exercise transactions in this Form 4 filing.

Indivior Pharmaceuticals, Inc. director Mark Stejbach received an equity grant of 6,518 shares of common stock in the form of restricted stock units. The RSUs vest immediately before the next annual stockholder meeting, as long as he continues serving the company, bringing his direct holdings to 27,087 shares.

Positive

  • None.

Negative

  • None.
Insider Stejbach Mark
Role null
Type Security Shares Price Value
Grant/Award Common Stock 6,518 $0.00 --
Holdings After Transaction: Common Stock — 27,087 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 6,518 shares Restricted Stock Units awarded on May 13, 2026
Price per share $0.0000 per share Grant/award acquisition, no cash paid
Post-transaction holdings 27,087 shares Common stock held directly after RSU grant
Transaction code A Grant, award, or other acquisition of common stock
Transaction direction acquire Equity grant increases director’s share position
Restricted Stock Units (RSUs) financial
"Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
vest financial
"The RSUs vest on the day immediately preceding the date of the annual meeting"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of the Issuer's stockholders regulatory
"the date of the annual meeting of the Issuer's stockholders following the date of grant"
continued service financial
"subject to the Reporting Person's continued service to the Issuer on the vesting date"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stejbach Mark

(Last)(First)(Middle)
10710 MIDLOTHIAN TURNPIKE
SUITE 125

(Street)
NORTH CHESTERFIELD VIRGINIA 23235

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/13/2026A6,518(1)A$027,087D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.
Remarks:
/s/Alice Givens, Power of Attorney05/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Indivior (INDV) director Mark Stejbach report in this Form 4?

He reported an award of 6,518 restricted stock units of Indivior common stock. These units are a form of equity compensation and increase his direct holdings to 27,087 shares, aligning his interests more closely with other shareholders over time.

Is the Indivior (INDV) Form 4 transaction a stock purchase or a grant?

The transaction is a grant of restricted stock units, not an open-market stock purchase. Stejbach received 6,518 RSUs at no cash cost, reflecting board-level equity compensation rather than a discretionary buy in the market.

When do Mark Stejbach’s new Indivior (INDV) RSUs vest?

The RSUs vest on the day immediately before Indivior’s next annual stockholder meeting. Vesting is contingent on Stejbach continuing to serve the company through that date, making the award dependent on ongoing service.

How many Indivior (INDV) shares does Mark Stejbach hold after this RSU grant?

After the RSU grant, Stejbach holds 27,087 shares of Indivior common stock directly. This figure includes the impact of the 6,518-share restricted stock unit award reported in the current insider filing.

What is a restricted stock unit (RSU) in the context of Indivior (INDV)?

A restricted stock unit is a promise to deliver one share of common stock in the future. For Indivior, each RSU equals one share, and delivery depends on meeting vesting conditions such as continued board or employee service.